Acromegaly
Also known as: Growth hormone excess in adults, GH hypersecretion syndrome, Adult hypersomatotropism
Acromegaly is a chronic endocrine disorder involving excess growth hormone and insulin-like growth factor 1, usually associated with a pituitary adenoma. Progressive tissue enlargement, joint symptoms and metabolic complications require endocrinology-led assessment and ongoing treatment. The supplied vascular meta-analysis identifies increased heart failure and atrial fibrillation risk. Pegvisomant pharmacovigilance findings support continued biochemical and liver monitoring, but reporting signals do not establish causation. Chinese medicine may be considered only as adjunctive, symptom-focused care after medical assessment, never to control tumour growth or replace surgery, medicines or radiotherapy. None of the supplied abstracts establishes acupuncture or herbal efficacy for acromegaly; the knee osteoarthritis protocol and thyroid nodule review cannot establish benefit in this condition.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to all scheduled endocrinology consultations and agreed biochemical, imaging, and cardiovascular monitoring; maintain prescribed treatment regimens without independent modification.
- •Engage in low-impact physical activity and joint-stabilisation exercises as directed by medical or physiotherapy professionals.
- •Maintain optimal sleep hygiene and report clinical indicators of obstructive sleep apnoea, such as snoring, nocturnal respiratory pauses, or excessive daytime somnolence, to a medical practitioner.
- •Adopt a nutritional plan designed to support glycaemic control and cardiovascular health, while maintaining a comprehensive record of symptoms, medications, and supplementary interventions.
Cautions & Contraindications
- •Defer elective acupuncture or herbal initiation when breathlessness, unstable palpitations or suspected decompensated heart failure is present; obtain medical assessment. This precaution is informed by the vascular burden in the supplied review, which does not directly study acupuncture safety.[]
- •Do not needle inflamed, infected or markedly reactive pegvisomant injection sites. Coordinate unexplained liver-test abnormalities with the prescribing team before considering herbs; the supplied pharmacovigilance signals do not prove a particular herb–drug interaction.[]
- •Do not use adjunctive care to interrupt pegvisomant therapy, biochemical monitoring or liver surveillance; medication changes belong with the treating team.[]
When to reassess or seek care again
Record baseline pain on a 0–10 scale, walking or hand-use tolerance, sleep disruption and adverse effects. Review after 2–4 weeks of adjunctive care; discontinue or revise if there is no meaningful symptom or functional improvement. Refer earlier for worsening pain, progressive sensory loss, new weakness, visual symptoms or cardiovascular concerns. GH, IGF-1, imaging and liver-test review remain endocrinology-led; symptom relief must not be interpreted as biochemical control.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Journal of pain research · 2026
- Endocrine · 2026
- International journal of general medicine · 2026
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
